Naunyn-Schmiedeberg's Archives of Pharmacology

, Volume 382, Issue 2, pp 151–158 | Cite as

Effects of bupropion on the forced swim test and release of dopamine in the nucleus accumbens in ACTH-treated rats

  • Yoshihisa Kitamura
  • Takahiko Yagi
  • Kouhei Kitagawa
  • Kazuaki Shinomiya
  • Hiromu Kawasaki
  • Masato Asanuma
  • Yutaka Gomita
ORIGINAL ARTICLE

Abstract

The dopamine reuptake inhibitor bupropion has clinically been proven to improve depression and treatment-resistant depression. We examined its influence on the duration of immobility during the forced swim test in adrenocorticotropic hormone (ACTH)-treated rats and further analyzed the possible role of dopamine receptors in this effect. Additionally, the mechanism by which bupropion acts in this model was explored specifically in relation to the site of action through the use of microinjections into the medial prefrontal cortex and nucleus accumbens. Bupropion significantly decreased the duration of immobility in normal and ACTH-treated rats. This effect was blocked by D2 and D3 receptor antagonists in normal rats. Furthermore, infusions of bupropion into the nucleus accumbens, but not medial prefrontal cortex, decreased the immobility of normal and ACTH-treated rats during the forced swim test. Bupropion treatment plus repeated ACTH treatment significantly increased the extracellular dopamine concentration. These findings suggest the antidepressant-like effect of bupropion to be related to levels of dopamine in the rat nucleus accumbens.

Keywords

Bupropion Treatment-resistant depression Forced swim test Dopamine receptor Dopamine release Nucleus accumbens 

Notes

Acknowledgments

This study was supported in part by a Grant-in-aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (No. 21590593).

References

  1. Carroll BJ, Curtis GC, Mendels J (1976) Neuroendocrine regulation in depression. Arch Gen Psychiatry 33:1039–1044PubMedGoogle Scholar
  2. Cassano P, Lattanzi L, Fava M, Navari S, Battistini G, Abelli M, Cassano GB (2005) Ropinirole in treatment-resistant depression: a 16-week pilot study. Can J Psychiatry 50:357–360PubMedGoogle Scholar
  3. Cervo L, Samanin R (1987) Evidence that dopamine mechanisms in the nucleus accumbens are selectively involved in the effect of desipramine in the forced swimming test. Neuropharmacology 26:1469–1472CrossRefPubMedGoogle Scholar
  4. Cervo L, Samanin R (1988) Repeated treatment with imipramine and amitriptyline reduced the immobility of rats in the swimming test by enhancing dopamine mechanisms in the nucleus accumbens. J Pharm Pharmacol 40:155–156PubMedGoogle Scholar
  5. Cooper BR, Hester TJ, Maxwell RA (1980) Behavioral and biochemical effects of antidepressant bupropion (Wellbutrin): evidence for selective blockade of desipramine uptake in vivo. J Pharmacol Exp Ther 215:127–134PubMedGoogle Scholar
  6. Fava M, Papakostas GI, Petersen T, Mahal Y, Quitkin F, Stewart J, McGrath P (2003) Switching to bupropion in fluoxetine-resistant major depressive disorder. Ann Clin Psychiatry 15:17–22PubMedGoogle Scholar
  7. Inoue T, Tsuchiya K, Miura J, Sakakibara S, Denda K, Kasahara T, Koyama T (1996) Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression. Biol Psychiatry 40:151–153CrossRefPubMedGoogle Scholar
  8. Izumi T, Inoue T, Kitagawa N, Nishi N, Shimanaka S, Takahashi Y, Kusumi I, Odagaki Y, Denda K, Ohmori T, Koyama T (2000) Open pergolide treatment of tricyclic and heterocyclic antidepressant-resistant depression. J Affect Disord 61:127–132CrossRefPubMedGoogle Scholar
  9. Jordan S, Kramer GL, Zukas PK, Moeller M, Petty F (1994) In vivo biogenic amine efflux in medial prefrontal cortex with imipramine, fluoxetine, and fluvoxamine. Synapse 18:294–297CrossRefPubMedGoogle Scholar
  10. Kitagawa K, Kitamura Y, Miyazaki T, Miyaoka J, Kawasaki H, Asanuma M, Sendo T, Gomita Y (2009) Effects of pramipexole on the duration of immobility during the forced swim test in normal and ACTH-treated rats. Naunyn Schmiedebergs Arch Pharmacol 380:59–66CrossRefPubMedGoogle Scholar
  11. Kitamura Y, Araki H, Gomita Y (2002) Influence of ACTH on the effects of imipramine, desipramine and lithium on duration of immobility of rats in the forced swim test. Pharmacol Biochem Behav 71:63–69CrossRefPubMedGoogle Scholar
  12. Kitamura Y, Fujitani Y, Kitagawa K, Miyazaki T, Sagara H, Kawasaki H, Shibata K, Sendo T, Gomita Y (2008) Effects of imipramine and bupropion on the duration of immobility of ACTH-treated rats in the forced swim test: involvement of the expression of 5-HT2A receptor mRNA. Biol Pharm Bull 31:246–249CrossRefPubMedGoogle Scholar
  13. Kulkarni SK, Bhutani MK, Bishnoi M (2008) Antidepressant activity of curcumin: involvement of serotonin and dopamine system. Psychopharmacology 201:435–442CrossRefPubMedGoogle Scholar
  14. Levant B, Nichole R, Vansell BA (1997) In vivo occupancy of D2 dopamine receptors by nafadotride. Neuropsychopharmacol 17:67–71CrossRefGoogle Scholar
  15. Li B, Suemaru K, Kitamura Y, Cui R, Gomita Y, Araki H (2007) Strategy to develop a new drug for treatment-resistant depression -Role of electroconvulsive stimuli and BDNF-. YAKUGAKU ZASSI 127:735–742CrossRefGoogle Scholar
  16. Maj J, Dziedzicka-Wasylewska M, Rogoz R, Rogoz Z, Skuza G (1996) Antidepressant drugs given repeatedly change the binding of the dopamine D2 receptor agonist [3H]N-0437, to dopamine D2 receptors in the rat brain. Eur J Pharmacol 304:49–54CrossRefPubMedGoogle Scholar
  17. Murphy BEP, Dhar V, Ghadirian AM, Chouinard G, Keller R (1991) Response to steroid suppression in major depression on resistant to antidepressant therapy. J Clin Psychopharmacol 11:121–126PubMedGoogle Scholar
  18. Pandey DK, Rajkumar R, Mahesh R, Radha R (2008) Depressant-like effects of parthenolide in a rodent behavioural antidepressant test battery. J Pharm Pharmacol 60:1643–1650CrossRefPubMedGoogle Scholar
  19. Piacentini MF, Clinckers R, Meeusen R, Sarre S, Ebinger G, Michotte Y (2003) Effects of bupropion on hippocampal neurotransmitters and on peripheral hormonal concentrations in the rat. J Appl Physiol 95:652–656PubMedGoogle Scholar
  20. Rogoz R, Dzicka-Wasylewska MD (1999) Effect of antidepressant drugs on the dopamine D2/D3 receptors in the rat brain differentiated by agonist and antagonist binding - an autoradiographic analysis. Naunyn-Schmiedeberg’s Arch pharmacol 359:178–186CrossRefGoogle Scholar
  21. Rogoz Z, Skuza G, Klodzinska A (2004) Anxiolytic- and antidepressant-like effects of 7-OH-DPAT, preferential dopamine D3 receptor agonist in rats. Pol J Pharmacol 56:519–526PubMedGoogle Scholar
  22. Sanchez C, Hyttel J (1999) Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 19:467–489CrossRefPubMedGoogle Scholar
  23. Serra G, Collu M, D’Aquila PS, De Montis GM, Gessa GL (1990) Possible role of dopamine D1 receptor in the behavioural supersensitivity to dopamine agonists induced by chronic treatment with antidepressants. Brain Res 527:234–243CrossRefPubMedGoogle Scholar
  24. Simon SX, Perry KW, Wong DT (2002) Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats. Neuropharmacology 42:181–190CrossRefGoogle Scholar
  25. Sonino N, Boscaro M, Ambroso G, Merola G, Mantero F (1986) Prolonged treatment of Cushing’s disease with metyrapone and aminoglutethimide. IRCS J Med Sci 14:485–486Google Scholar
  26. Tanda G, Carboni E, Frau R, Di Chiara G (1994) Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential? Psychopharmacology 93:193–200Google Scholar
  27. Willner P (1997) The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychopharmacol 12(Suppl 3):S7–S14CrossRefPubMedGoogle Scholar
  28. Yamada J, Sugimoto Y, Yamada S (2004) Involvement of dopamine receptors in the anti-immobility effects of dopamine re-uptake inhibitors in the forced swimming test. Eur J Pharmacol 504:207–211CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Yoshihisa Kitamura
    • 1
  • Takahiko Yagi
    • 1
  • Kouhei Kitagawa
    • 1
  • Kazuaki Shinomiya
    • 1
  • Hiromu Kawasaki
    • 2
  • Masato Asanuma
    • 3
  • Yutaka Gomita
    • 4
  1. 1.Department of Pharmaceutical Care and Health Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical SciencesOkayama UniversityKita-kuJapan
  2. 2.Department of Clinical Pharmaceutical Science, Graduate School of Medicine, Dentistry and Pharmaceutical SciencesOkayama UniversityKita-kuJapan
  3. 3.Department of Brain Science, Graduate School of Medicine, Dentistry and Pharmaceutical SciencesOkayama UniversityKita-kuJapan
  4. 4.Shujitsu University School of PharmacyNaka-kuJapan

Personalised recommendations